clarithromycin has been researched along with Scleroderma, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bambara, LM; Biasi, D; Caramaschi, P; Mahamid, H | 1 |
| Evan, G; Jokinen, CH; Yeh, I | 1 |
2 other study(ies) available for clarithromycin and Scleroderma, Systemic
| Article | Year |
|---|---|
Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
Topics: Aged; Anti-Bacterial Agents; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingers; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2010 |
Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms.
Topics: Anti-Bacterial Agents; Clarithromycin; Diagnosis, Differential; Etanercept; Granuloma, Plasma Cell; Humans; Immunocompromised Host; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Prednisone; Receptors, Tumor Necrosis Factor; Sarcoma; Scleroderma, Systemic; Skin Diseases; Soft Tissue Neoplasms | 2011 |